Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Feasibility, and Preliminary Efficacy of Non-invasive Gamma Neuromodulation in Individuals With Schizophrenia Spectrum Disorders

NCT07342465 is registered in ClinicalTrials.gov with Massachusetts Institute of Technology as lead sponsor.

NCT NCT07342465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07342465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Feasibility, and Preliminary Efficacy of Non-invasive Gamma Neuromodulation in Individuals With Schizophrenia Spectrum Disorders
Lead sponsor
Massachusetts Institute of Technology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia spectrum disorders